GAMMA Investing LLC Buys 822 Shares of Moderna, Inc. (NASDAQ:MRNA)

GAMMA Investing LLC grew its stake in Moderna, Inc. (NASDAQ:MRNA) by 37.8% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,994 shares of the company’s stock after purchasing an additional 822 shares during the quarter. GAMMA Investing LLC’s holdings in Moderna were worth $319,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Allworth Financial LP lifted its holdings in Moderna by 6.5% during the 4th quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock worth $165,000 after purchasing an additional 101 shares during the last quarter. TIAA Trust National Association increased its position in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock worth $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC grew its stake in Moderna by 17.8% during the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock worth $76,000 after buying an additional 115 shares in the last quarter. EverSource Wealth Advisors LLC raised its position in shares of Moderna by 32.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 475 shares of the company’s stock valued at $47,000 after buying an additional 116 shares in the last quarter. Finally, Geo Capital Gestora de Recursos Ltd lifted its holdings in shares of Moderna by 0.4% during the 4th quarter. Geo Capital Gestora de Recursos Ltd now owns 32,339 shares of the company’s stock worth $3,216,000 after acquiring an additional 144 shares during the period. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Performance

NASDAQ MRNA opened at $133.27 on Thursday. The company has a debt-to-equity ratio of 0.04, a current ratio of 4.03 and a quick ratio of 3.91. The company has a fifty day moving average price of $130.56 and a 200-day moving average price of $109.54. Moderna, Inc. has a 1 year low of $62.55 and a 1 year high of $170.47. The firm has a market cap of $51.07 billion, a price-to-earnings ratio of -8.50 and a beta of 1.54.

Moderna (NASDAQ:MRNA) last posted its earnings results on Thursday, May 2nd. The company reported ($3.07) EPS for the quarter, topping the consensus estimate of ($3.59) by $0.52. The firm had revenue of $167.00 million for the quarter, compared to analysts’ expectations of $93.26 million. Moderna had a negative net margin of 115.82% and a negative return on equity of 20.10%. The company’s quarterly revenue was down 91.0% compared to the same quarter last year. During the same quarter last year, the firm earned $0.19 EPS. As a group, equities research analysts predict that Moderna, Inc. will post -7.46 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on MRNA. UBS Group upped their target price on Moderna from $143.00 to $151.00 and gave the stock a “buy” rating in a research note on Tuesday, May 7th. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research note on Monday, June 3rd. HSBC reaffirmed a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a research note on Monday, February 26th. Evercore ISI started coverage on Moderna in a research report on Tuesday, May 14th. They issued an “in-line” rating and a $120.00 target price for the company. Finally, Oppenheimer raised their price objective on shares of Moderna from $163.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, June 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $129.02.

Insider Activity at Moderna

In other Moderna news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the completion of the sale, the president now directly owns 1,457,089 shares in the company, valued at $201,311,416.24. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. In related news, CFO James M. Mock sold 705 shares of the stock in a transaction on Monday, April 8th. The shares were sold at an average price of $101.93, for a total transaction of $71,860.65. Following the transaction, the chief financial officer now owns 5,048 shares of the company’s stock, valued at approximately $514,542.64. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, President Stephen Hoge sold 15,000 shares of the company’s stock in a transaction dated Monday, June 17th. The shares were sold at an average price of $138.16, for a total transaction of $2,072,400.00. Following the sale, the president now owns 1,457,089 shares of the company’s stock, valued at $201,311,416.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 411,255 shares of company stock worth $55,846,531. 15.70% of the stock is owned by company insiders.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.